ANTIBODY DEPENDENT COMPLEMENT MEDIATED KILLING OF HIV-2 INFECTED CELLS

抗体依赖性补体介导杀死 HIV-2 感染细胞

• 批准号: 5200826
• 负责人: M P SELVAM
• 金额: --
• 依托单位: BUREAU OF HEALTH PLANNING AND RESOURCES DEVELOPMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5200826
• 关键词: HIV envelope protein gp120; HIV envelope protein gp160; HIV infections; animal tissue; complement; complement pathway; cytolysis; human immunodeficiency virus 1; human immunodeficiency virus 2; human tissue; recombinant proteins; serum; virus antigen

It was shown that by the classical pathway of complement activation, it is possible to kill HIV-1 infected cells. It was found that fresh sera of Rabbit showed a dose dependent viral inactivating property against cell free HIV-1. Further in the present project, it is possible to elucidate the mechanism to understand the lack of activity of human serum against HIV-1. With the same idea, presently the work is ongoing to test a panel of HIV-2 sera for their ability to activate human complement by the classical pathway mediated Membrane Attack Complex System (MACS). Activation is being assessed by the C3-complement component deposition using anti C3 conjugated to FITC. Analysis of complement mediated cytolysis of infected cells using serum samples against recombinant HIV-1 env or core antigens speculates that env gp160/120 and gag p24 acts as target antigens for antibody and complement mediated cytolysis.

研究表明，通过补体激活的经典途径， 可以杀死HIV-1感染的细胞。 发现新鲜血清 的兔显示出剂量依赖性的病毒灭活特性， 无细胞HIV-1 此外，在本项目中，有可能 阐明人血清缺乏活性的机制 对抗HIV-1。 本着同样的想法，目前正在进行的工作是， 测试一组HIV-2血清激活人类补体能力 经典途径介导的膜攻击复合系统（MACS）。 通过C3补体成分沉积评估激活 使用与FITC缀合的抗C3。 补体介导的分析 使用抗重组HIV-1的血清样品的感染细胞的细胞溶解 env或核心抗原推测，env gp 160/120和gagp 24作为 用于抗体和补体介导的细胞溶解的靶抗原。